Tenax Therapeutics Inc

TENX

12.730USD

+0.370+2.99%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

Tenax Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

43 / 392

Overall Ranking

149 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Tenax Therapeutics Inc Highlights

StrengthsRisks

Tenax Therapeutics, Inc. is a Phase 3 development-stage pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company's products include TNX-201 (oral enteric-coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 and TNX-102. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Undervalued

The company’s latest PE is -17.13, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 6.62M shares, increasing 23.20% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 255.66K shares of this stock.

Analyst Rating

Based on 5 analysts

Strong Buy

Current Rating

25.250

Target Price

+104.29%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Tenax Therapeutics Inc is 6.95, ranking 180 out of 392 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.95

Change

0



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.99

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Tenax Therapeutics Inc is 8.79, ranking 20 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -17.13, which is -122.77% below the recent high of 3.90 and -43.52% above the recent low of -24.59.

Score

Industry at a Glance

Previous score

8.79

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 43/392

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Tenax Therapeutics Inc is 9.20, ranking 9 out of 392 in the Biotechnology & Medical Research industry. The average price target is 23.00, with a high of 30.00 and a low of 14.00.

Score

Industry at a Glance

Previous score

9.20

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Tenax Therapeutics Inc is 6.19, ranking 275 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 16.67 and the support level at 10.49, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.08

Change

0.11

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-02-06

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Ikarian Capital LLC

967.60K

--

Janus Henderson Investors

623.73K

+274.24%

Perceptive Advisors LLC

439.14K

--

VR Adviser, LLC

437.71K

+344.09%

Invus Public Equities Advisors, LLC

427.14K

+21.20%

RTW Investments L.P.

378.35K

--

Boothbay Fund Management, LLC

352.21K

--

Dellora Investments LP

351.07K

--

Point72 Asset Management, L.P.

Star Investors

339.63K

--

BVF Partners L.P.

339.55K

--



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Tenax Therapeutics Inc is 2.98, ranking 181 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 1.40. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.

Tenax Therapeutics Inc

TENX

7.43 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.60 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ascendis Pharma A/S

ASND

8.53 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ionis Pharmaceuticals Inc

IONS

8.38 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

IQVIA Holdings Inc

IQV

8.37 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BioCryst Pharmaceuticals Inc

BCRX

8.17 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment